Whole-Genome Sequence Characterization of Respiratory Syncytial Virus in the Post-COVID-19 Era

Strategic Insights -

Research findings on Coronavirus - COVID-19 are discussed in a new report, highlighting the ongoing genetic evolution of Respiratory Syncytial Virus (RSV) in the post-pandemic era. The study, conducted by researchers at Johns Hopkins University School of Medicine, utilized whole-genome sequencing to monitor the effectiveness of RSV vaccines and the emergence of antibody-resistant genotypes.

Key Takeaways:

  • The study highlighted the importance of genomic surveillance in monitoring the genetic evolution of RSV, particularly in the post-COVID-19 era.
  • Whole-genome sequencing of 336 RSV-positive samples revealed the predominance of RSV-A (94.9%) and the regional evolution of clade A.D.1.6 (68.34%).
  • The study found that comorbidities, including immunosuppression, were significantly associated with severe clinical outcomes.
  • Phylogenetic analyses revealed tight clustering and low intra-clade diversity, indicating the ongoing genetic evolution of RSV-A.
  • Amino acid substitutions were detected across surface and internal proteins, potentially affecting the effectiveness of vaccines, monoclonal antibodies, or antivirals.
  • Comorbidities, including immunosuppression, were significantly associated with severe clinical outcomes.
  • Half of the infections occurred in children aged 1-5 years (56.2%), highlighting the importance of integrating RSV genomic and epidemiological surveillance.
  • The study concluded that ongoing antiviral drug development, recent approvals of new vaccines, and continued use of protective antibody therapies require integrated RSV genomic and epidemiological surveillance.

Statistics:

  • 336 RSV-positive samples were collected for the study.
  • RSV-A accounted for 94.9% of the samples.
  • The regional evolution of clade A.D.1.6 was estimated at 68.34%.
  • 56.2% of infections occurred in children aged 1-5 years.
  • Comorbidities, including immunosuppression, were significantly associated with severe clinical outcomes.

Sources:

  • NewsRx. New COVID-19 Study Results Reported from Johns Hopkins University School of Medicine (Whole-genome sequence characterization of respiratory syncytial virus in the Johns Hopkins Health System during the 2024-2025 respiratory season). Medical Letter on the CDC & FDA. October 26, 2025; p 103.
  • Microbiology Spectrum can be contacted at: Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA.